PHESGO® is a subcutaneous combination of pertuzumab and trastuzumab for HER2-positive breast cancer, designed to reduce treatment time.
Related products
Zoladex 10.8mg Inj. x 1 (NAFDAC)
Ozempic 0.25mg Injection (UK)
Semaglutide
Xeloda 500mg x 120Caps (NAFDAC)
Capecitabine
Wegovy 1mg/0.5ml Inj. x 1Pen
Semaglutide Injection

















